It is associated with pathogenic germ-line variants in TP53 and has an estimated penetrance of 80–90%, higher than in other cancer pre-disposition syndromes, for example that associated with BRCA1 or BRCA2 [2,3,4]. The gene discussed is TP53; the disease is cancer.